Amgen Inc. entered into a consent order and judgment with Henlius and Organon on March 31 2026 that resolves the Biologics Price Competition and Innovation Act (BPCIA) patent litigation over the company’s denosumab product. The order declares all 26 patents asserted by Amgen to be valid, enforceable, and infringed by the defendants’ denosumab biosimilars, and dismisses all remaining claims and counterclaims with prejudice.
The settlement confirms the validity of Amgen’s patents covering denosumab, pharmaceutical compositions containing denosumab, and methods of manufacture. Henlius’ biosimilar, BILPREVDA®, and Organon’s BILDYOS® are the products at issue. The consent order does not specify launch dates for either biosimilar, nor does it disclose any financial terms, which remain confidential.
Amgen’s position is reinforced by a series of prior agreements with other biosimilar manufacturers, including Celltrion, Sandoz, Fresenius, Accord, Samsung Bioepis, Biocon, and Hikma/Gedeon. The company’s flagship denosumab products, Prolia® and XGEVA®, generated U.S. sales of $2.978 billion and $1.355 billion, respectively, in fiscal year 2025, underscoring the commercial importance of protecting these patents.
The settlement strengthens Amgen’s intellectual‑property strategy and limits the risk of biosimilar competition for its core denosumab franchise. While the order confirms patent validity, it does not grant immediate market access to Henlius or Organon, leaving launch timing uncertain and subject to regulatory approval. Amgen continues to face pending BPCIA litigation against Alkem, Dr. Reddy’s/Alvotech, and Amneal, indicating an ongoing defensive posture in the biosimilar landscape.
Amgen’s consistent success in settling denosumab patent disputes signals a robust IP defense strategy that preserves revenue streams from Prolia® and XGEVA® while allowing the company to focus on expanding its biosimilar portfolio in a highly competitive market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.